TNFα inhibitors as targets for protective therapies in MSA: a viewpoint
- PMID: 30975183
- PMCID: PMC6458780
- DOI: 10.1186/s12974-019-1477-5
TNFα inhibitors as targets for protective therapies in MSA: a viewpoint
Abstract
Multiple system atrophy (MSA) is a unique and fatal α-synucleinopathy associated with oligodendroglial inclusions and secondary neurodegeneration affecting striatum, substantia nigra, pons, and cerebellum. The pathogenesis remains elusive; however, there is emerging evidence suggesting a prominent role of neuroinflammation. Here, we critically review the relationship between αS and microglial activation depending on its aggregation state and its role in neuroinflammation to explore the potential of TNFα inhibitors as a treatment strategy for MSA and other neurodegenerative diseases.
Keywords: Disease-modifying treatment; Multiple system atrophy; Neurodegeneration; Neuroinflammation; TNFα; TNFα inhibitors.
Conflict of interest statement
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable as no patients/participants are involved in this review.
Competing interests
The authors declare that they have no competing interests.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources